Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report

Seeking Alpha03:44

J&J Talc Claimants Lose Bid to Block Bankruptcy Bid

Seeking AlphaJun 29 21:11

J&J Reports Positive Phase 3 Data for Nipocalimab for Neuromuscular Disease

Seeking AlphaJun 29 00:45

Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial

Johnson & Johnson (JNJ) said Friday results from a phase 3 study of nipocalimab in generalized myasthenia gravis were "positive." Patients treated with nipocalimab plus standard of care achieved super

MT NewswiresJun 29 00:28

Express News | J&J - Papillon Study Met Its Primary Endpoint

BreakingsJun 29 00:01

Express News | Rybrevant®▼ (Amivantamab) in Combination With Chemotherapy Is First Therapy Approved by European Commission for First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer With Activating Egfr Exon 20 Insertion Mutations

BreakingsJun 29 00:00